How I treat chronic graft-versus-host disease

Blood

Volumn 97, Issue 5, 2001, Pages 1196-1201

  Vogelsang, Georgia B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CLOFAZIMINE; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN A; DEXAMETHASONE; ETRETIN; ETRETINATE; FLUOCINONIDE; GANCICLOVIR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENICILLIN G; PENTOSTATIN; PETROLATUM; PREDNISONE; STEROID; TACROLIMUS; THALIDOMIDE;

APLASTIC ANEMIA; BLOOD DISEASE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG INDUCED DISEASE; DRY SKIN; ENDOCARDITIS; GRAFT VERSUS HOST REACTION; HERPES; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSIOTHERAPY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PUVA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCLERODERMA; STEM CELL TRANSPLANTATION; STREPTOCOCCUS INFECTION;

EID: 0035282746     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1196     Document Type: Review

References (34)

1. Differential cytokine expression in acute and chronic murine graft-versus-host disease
2. Preferential activation of Th2 cells in chronic murine graft-versus-host reaction
3. Cyclosporine-induced syngeneic graft-versus-host disease: Recognition of self-MHC class II antigens in vivo
4. Minor histocompatibility antigens
5. Graft-versus-host disease: The influence of type 1 and type 2 T cell cytokines
6. Graft-versus-host disease and the Th1/Th2 paradigm
7. Chronic graft versus host disease in other late complications of bone marrow transplantation
8. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation
9. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids
10. Long-term cyclosporine therapy may decrease the risk of chronic graft-versus-host disease
11. Cyclosporine A and graft-versus-host disease
12. Second marrow infusion for poor graft function after allogeneic marrow transplantation
13. Tranfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease
14. European multicenter study of chronic graft versus host disease: The role of cytomegalovirus serology in recipients and donors, acute graft-versus-host disease, and splenectomy
15. Cytomegalovirus infection after marrow transplantation for aplastic anemia
16. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation
17. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
18. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease: Committee of the International Bone Marrow Transplant Registry
19. Development of a prognostic model for grading chronic graft-versus-host disease
20. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation
21. Alternating day cyclosporine and prednisone for treatment of high risk chronic graft-versus-host disease
22. Predictors of death from chronic graft versus host disease after bone marrow transplantation
23. Thalidomide for the treatment of chronic graft-versus-host disease
24. FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation
25. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic GVHD
26. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease
27. Treatment of chronic graft-versus-host disease with clofazimine
28. The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease
29. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction
30. PUVA therapy for drug resistant graft-versus-host disease
31. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA)
32. Low-dose total lymphoid irradiation for extensive, drug resistant chronic graft versus host disease
33. Total lymphoid irradiation for treatment of drug resistant chronic GVHD
34. Graft-vs-host disease